Press Release: Johnson & Johnson : TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in
Read full article »
Johnson & Johnson is a New Jersey-based firm that engages in research, manufacturing and sale of healthcare products including consumer, pharmaceutical and medical devices.
Read more